Cytotoxic Payloads for Antibody-Drug Conjugates

ホーム
> 洋書
> 英文書
> Medical

個数：

ポイントキャンペーン

Cytotoxic Payloads for Antibody-Drug Conjugates

Thurston, David (EDT)/ Jackson, Paul J M (EDT)

ウェブストア価格 ¥53,856（本体¥48,960）
Royal Society of Chemistry（2019/07発売）
外貨定価 US$ 250.00
読書週間ポイント2倍キャンペーン対象商品（～11/9）
ポイント 978pt

在庫がございません。海外の書籍取次会社を通じて出版社等からお取り寄せいたします。
通常6～9週間ほどで発送の見込みですが、商品によってはさらに時間がかかることもございます。
【重要ご説明事項】
1. 納期遅延や、ご入手不能となる場合がございます。
2. 複数冊ご注文の場合は、ご注文数量が揃ってからまとめて発送いたします。
3. 美品のご指定は承りかねます。

●3Dセキュア導入とクレジットカードによるお支払いについて

【入荷遅延について】
世界情勢の影響により、海外からお取り寄せとなる洋書・洋古書の入荷が、表示している標準的な納期よりも遅延する場合がございます。
おそれいりますが、あらかじめご了承くださいますようお願い申し上げます。

◆画像の表紙や帯等は実物とは異なる場合があります。

◆ウェブストアでの洋書販売価格は、弊社店舗等での販売価格とは異なります。
また、洋書販売価格は、ご注文確定時点での日本円価格となります。
ご注文確定後に、同じ洋書の販売価格が変動しても、それは反映されません。

製本 Hardcover:ハードカバー版／ページ数 502 p.
言語 ENG
商品コード 9781788010771
DDC分類 615.37

Full Description

Antibody-drug conjugates (ADCs) represent one of the most promising and exciting areas of anticancer drug discovery. Five ADCs are now approved in the US and EU [i.e., ado-trastuzumab emtansine (Kadcyla™), brentuximab vedotin (Adcetris™), inotuzumab ozogamicin (Besponsa™), gemtuzumab ozogamicin (Mylotarg™) and moxetumomab pasudotox-tdfk (Lumoxiti®)] and over 70 others are in various stages of clinical development, with impressive interim results being reported for many.

The technology is based on the concept of delivering a cytotoxic payload selectively to cancer cells by attaching it to an antibody targeted to antigens on the cell surfaces. This approach has several advantages including the ability to select patients as likely responders based on the presence of antigen on the surface of their cancer cells and a wider therapeutic index, given that ADC targeting enables a more efficient delivery of cytotoxic agents to cancer cells than can be achieved by conventional chemotherapy, thus minimising systemic toxicity.

Although there are many examples of antibodies that have been developed for this purpose, along with numerous linker technologies used to attach the cytotoxic agent to the antibody, there is presently a relatively small number of payload molecules in clinical use. The purpose of this book is to describe the variety of payloads used to date, along with a discussion of their advantages and disadvantages and to provide information on novel payloads at the research stage that may be used clinically in the future.

Introduction to Antibody-Drug Conjugates (ADCs);

Design Factors Important for Antibody-Drug Conjugate (ADC) Payloads;

Use of Molecular Modelling Techniques in Antibody-Drug Conjugate (ADC) Payload Discovery and Development;

Auristatin Payloads for Antibody-Drug Conjugates (ADCs);

Maytansinoid Payloads for Antibody-Drug Conjugates (ADCs);

Colchicine-, Vinblastine-, Taxol- and Eribulin-based Payloads for Antibody-Drug Conjugates (ADCs);

Traditional Cytotoxic Agents as Antibody-Drug Conjugate (ADC) Payloads;

Topoisomerase Inhibitors as Antibody-Drug Conjugate (ADC) Payloads;

Duocarmycins as Antibody-Drug Conjugate (ADC) Payloads;

CXI Dimers as Antibody-Drug Conjugate (ADC) Payloads;

Duocarmycin-PBD Dimers as Antibody-Drug Conjugate (ADC) Payloads;

Calicheamicins as Antibody-Drug Conjugate (ADC) Payloads;

Pro-pyrrolobenzodiazepines and Conjugates as Antibody-Drug Conjugate (ADC) Payloads;

Pyrrolobenzodiazepine Dimers as Antibody-Drug Conjugate (ADC) Payloads;

Indolinobenzodiazepine Dimers (IGNs) as Antibody-Drug Conjugate (ADC) Payloads;

Pyridinobenzodiazepines (PDDs) as Sequence-selective DNA Mono-alkylating Antibody-Drug Conjugate (ADC) Payloads;

Splicing Inhibitors as Antibody-Drug Conjugate (ADC) Payloads;

Tubulysins as Antibody-Drug Conjugate (ADC) Payloads;

Amatoxins as RNA Polymerase II Inhibiting Antibody-Drug Conjugate (ADC) Payloads;

Protein Toxins as Antibody-Drug Conjugate (ADC) Payloads;

Occupational Health and Safety Considerations for the Handling and Manufacture of Antibody-Drug Conjugate (ADC) Payloads;

The Future of Antibody-Drug Conjugate (ADC) Payloads